Highest-materiality recent filing
DBV Technologies H1 2026 net loss $98M; BLA submission for peanut patch delayed to Q3 2026
Net loss of $98.0M for H1 2026 vs $69.0M for H1 2025; Q2 net loss $50.4M.
DBV Technologies delays VIASKIN Peanut Patch BLA submission to Q3 2026 after FDA feedback
BLA submission for VIASKIN Peanut Patch in children aged 4-7 delayed to Q3 2026.
DBV Technologies grants CEO Daniel Tassé 4.06M PSUs tied to FDA approval of Viaskin Peanut
4,060,000 PSUs awarded to CEO; vesting conditioned on FDA approval of Viaskin Peanut BLA.
DBV Technologies grants CEO 1.74M PSUs tied to FDA acceptance of Viaskin Peanut BLAs
1,740,000 PSUs granted to CEO Daniel Tassé with grant date May 5, 2026.
DBV Technologies reports Q1 net loss of $47.6M; cash of $229M into Q2 2027
Net loss of $47.6M ($0.11 per share) vs $27.1M ($0.26) in Q1 2025; loss per share improved due to equity base from PIPE.
DBV Technologies FY2025 net loss $147M; cash runway into Q2 2027; BLA on track H1 2026
Net loss of $147M for FY2025, compared to $113.9M in FY2024; diluted EPS -$1.05.
82.8% of treated children increased eliciting dose at month 12 vs ~48% placebo; 60.1% increased by ≥2 doses vs 23.4% placebo.
DBV Technologies secures €166.7M from full exercise of warrants after positive VITESSE trial
€166.7M gross proceeds from full exercise of ABSA Warrants (34.1M) and BS Warrants (71.0M) issued March 2025.
DBV Technologies reports positive Phase 3 VITESSE results; BLA submission on track for H1 2026
VITESSE met primary endpoint: response rate 46.6% vs 14.8% placebo (p<0.001); lower bound CI 24.5% >15% threshold.
Net loss $33.2M in Q3 2025 ($0.24/share); nine-month loss $102.1M ($0.82/share), wider than prior year.
DBV Technologies establishes $150M ATM equity program via Citizens JMP; up to 50% dilution
ATM program allows sale of up to $150M in ADSs (each representing 5 ordinary shares) on Nasdaq through Citizens JMP.
DBV Tech Q2 2025 net loss $41.9M; cash $103.2M; going concern doubt persists
Q2 2025 net loss of $41.9M vs $33.1M in Q2 2024, driven by R&D spend on COMFORT Toddlers study.
DBV Tech Q1 cash $13M, net loss $0.26/share; new $306.9M financing to fund into June 2026
Cash used in operations $19.7M; cash balance fell to $13.0M as of March 31, 2025 from $32.5M.
DBV Technologies raises up to $306.9M via private placement for Viaskin Peanut BLA
Gross proceeds up to $306.9M: $125.5M upfront plus up to $181.4M if all warrants exercised.
DBVT: FDA agrees on safety data for Viaskin BLA in 4-7 yr olds; cash only into Apr 2025
FDA aligns: safety data from VITESSE Phase 3 and OLE sufficient for BLA; no COMFORT Children study needed; BLA filing 1H 2026, potential launch acceleration ~1 year.
DBV Technologies reports positive 3-year EPITOPE OLE data; 68.2% passed food challenge at month 36
68.2% of toddlers completed oral food challenge (~12-14 peanut kernels) without meeting stopping criteria at month 36, vs 30.7% at month 12.
FDA confirmed Phase 3 EPITOPE efficacy data serves as intermediate endpoint for Accelerated Approval.
DBV Technologies plans 1-for-5 ADS reverse split effective Nov 29 to regain Nasdaq compliance
ADS ratio changes from 1 ADS = 1 ordinary share to 1 ADS = 5 ordinary shares.
DBV Technologies reports Q3 cash $46.4M; going concern doubt, cash runway into Q1 2025
Net loss of $90.9M for 9M ended Sep 30 2024 vs $61.5M prior year; Q3 net loss $30.4M.
FDA confirmed Accelerated Approval pathway for Viaskin Peanut patch in 1-3 year-olds; COMFORT safety study (n=300-350) to start Q2 2025.
DBV completes VITESSE Phase 3 screening early; topline data expected Q4 2025
Screening closed in August 2024, ahead of schedule; enrollment exceeded original goal.
DBV reports Q2 net loss $33.1M, cash $66.2M, going concern doubt; VITESSE on track
Q2 net loss of $33.1M (US GAAP), basic EPS -$0.34 vs -$0.26 in Q2 2023.
DBVT granted second 180-day compliance period for Nasdaq bid-price rule; transfer to Capital Market
Nasdaq transferred DBVT ADS listing from Global Select to Capital Market tier effective June 20, 2024.
DBV Technologies delays ADS ratio change to June 7, 2024; 1-for-2 reverse split
ADS ratio change expected effective June 7, 2024, previously planned June 3.
DBV Technologies shareholders approve reverse split and ATM program at AGM
Shareholders approved a 10:1 reverse split (par value to €1); 46.6M for, 2.3M against.
DBV Technologies reports Q1 net loss $27.3M; cash runway only through Dec 2024, substantial doubt
Cash & equivalents $101.5M as of March 31, down from $141.4M at Dec 31, 2023.
DBV Technologies reports FY2023 net loss $72.7M; cash $141.4M; substantial doubt about going concern
Net loss $72.7M ($0.76/share) vs $96.3M in 2022; operating expenses $92.2M, with R&D $60.2M.
DBV Technologies receives Nasdaq deficiency notice for ADS bid price below $1.00
Nasdaq letter on Dec 20, 2023: DBVT ADS bid price below $1.00 for 30 consecutive business days.
After 24 months, 81.3% of subjects reached eliciting dose >=1,000 mg peanut protein vs 64.2% at 12 months.
DBV reports Q3 net loss, $149M cash; FDA clarifies COMFORT studies; terminates Nestlé deal
FDA provided written feedback harmonizing COMFORT Toddlers/Children protocol design; COMFORT Toddlers uses same eligibility as EPITOPE (DBPCFC required).
FDA agreed on COMFORT Toddlers design: 6-month, 3:1 randomization, ~400 subjects, ages 1-3, no oral food challenge required.
DBV Technologies announces NEJM publication of Phase 3 EPITOPE trial for Viaskin Peanut in toddlers
NEJM published Phase 3 EPITOPE data showing Viaskin Peanut statistically superior to placebo in desensitizing toddlers (1-3 years) to peanut.
DBV Technologies Q1 net loss widens to $20.5M; cash drops to $192.3M
Cash and equivalents $192.3M as of March 31, 2023, down from $209.2M at Dec 31, 2022.
DBV gets FDA path for Viaskin Peanut BLA in toddlers 1-3; EPITOPE efficacy confirmed
FDA confirmed Phase 3 EPITOPE met primary endpoint; no additional efficacy study required.
DBV screens first patient in VITESSE Phase 3 peanut allergy trial for ages 4–7
First patient screened at Midwest Allergy Sinus Asthma in Normal, Illinois for VITESSE Phase 3 trial.
DBV Technologies FY2022 net loss $96.3M; cash $209.2M after $180.4M PIPE
Net loss of $96.3M ($1.24 per share) vs $97.8M ($1.78) in 2021; operating expenses down 3% to $101.5M.
On October 16, 2023, DBV Technologies S.A. (the “Company”) announced the appointment of Virginie Boucinha as the Company’s Chief Financial Officer and principal accounting officer, effective as of November 6, 2023.
Mr. Robitaille will continue to serve as an executive officer of the Company until November 17, 2023;
On October 16, 2023, DBV Technologies S.A. (the “Company”) announced the appointment of Virginie Boucinha as the Company’s Chief Financial Officer and principal accounting officer, effective as of November 6, 2023.
In addition, the Company announced that Sébastien Robitaille, who currently serves as the Company’s Chief Financial Officer, will separate employment with the Company effective November 17, 2023 to pursue other opportunities.
In connection with Ms. Monges’s resignation, the Board appointed Timothy E. Morris, currently serving as independent director and member of the Audit Committee of the Board (the “Audit Committee”), as the Chairperson of the Audit Committee, in replacement of Ms. Monges.
In addition, Daniele Guyot-Caparros was appointed to the Board of the Company effective immediately, to fill the vacancy created by the resignation of Ms. Monges.
On October 3, 2022, Viviane Monges notified the Board of Directors (the “Board”) of DBV Technologies S.A. (the “Company”) of her resignation from the Board and all committees thereof, effective immediately.
Max materiality 0.95 · Median 0.70 · Most common event other_material